Stockscreener 앱 받기
1.98
4.35%
-0.09
전일 마감가:
$2.07
열려 있는:
$2.03
하루 거래량:
122.62K
Relative Volume:
0.06
시가총액:
$6.51M
수익:
$12.99M
순이익/손실:
$-23.72M
주가수익비율:
-0.0204
EPS:
-97.2514
순현금흐름:
$-23.28M
1주 성능:
-1.00%
1개월 성능:
-36.74%
6개월 성능:
-97.15%
1년 성능:
-99.30%
1일 변동 폭
$1.95
$2.0515
1주일 범위
$1.8701
$2.16
52주 변동 폭
$1.7197
$381.10
Aptevo Therapeutics Inc Stock (APVO) Company Profile
명칭
Aptevo Therapeutics Inc
전화
206-838-0500
주소
2401 4TH AVE., SEATTLE, WA
APVO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
APVO
Aptevo Therapeutics Inc
|
1.98 | 6.81M | 12.99M | -23.72M | -23.28M | -97.25 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Aptevo Therapeutics Inc Stock (APVO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2018-11-05 | 개시 | Ladenburg Thalmann | Buy |
| 2017-10-05 | 재개 | Piper Jaffray | Overweight |
Aptevo Therapeutics Inc 주식(APVO)의 최신 뉴스
Published on: 2025-08-21 02:09:31 - classian.co.kr
What’s the RSI of Aptevo Therapeutics Inc. stockTrade Performance Summary & High Return Stock Watch Alerts - mustnews.co.kr
APVO stock plunges to 52-week low at $3.62 amid steep annual decline - MSN
Aptevo Highlights APVO442, a CD3-Directed Preclinical Candidate for Prostate Cancer - MarketScreener
Aptevo highlights prostate cancer bispecific antibody candidate By Investing.com - Investing.com Nigeria
Aptevo's New Prostate Cancer Drug Shows Promise with Targeted Immune Response Technology - Stock Titan
Aptevo Therapeutics APVO Q2 2025 Earnings Preview Downside Risk Over Lack of Revenue Growth - AInvest
Aptevo Therapeutics Reports Q2 2025 Financials and Business Update, Raises $15.9M, and Advances Mipletamig and APVO455 Candidates - AInvest
Aptevo Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Aptevo Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 - MarketScreener
Aptevo Therapeutics Reports 2Q25 Financial Results And Provides A Business Update | APVO Stock News - GuruFocus
Aptevo Therapeutics Inc. SEC 10-Q Report - TradingView
Aptevo Therapeutics reports Q2 EPS ($8.40) vs. ($1,236.96) last year - TipRanks
Aptevo Reports 85% Remission in Q2 - The Motley Fool
Aptevo Therapeutics Reports 2Q25 Financial Results And Provides A Business Update - ACCESS Newswire
Aptevo Reports Breakthrough: 85% Remission in AML Trial, Launches New Solid Tumor Program - Stock Titan
Evaluating Aptevo Therapeutics Inc. with trendline analysisReal Time Trade Execution Alert Plan - Newser
Is Aptevo Therapeutics Inc. likely to announce a buybackBest ROI Stocks This Month - sisain.net
Why Aptevo Therapeutics Inc. stock attracts strong analyst attentionWeekly Chart Watchlist with Trade Guidance - Newser
Historical volatility pattern of Aptevo Therapeutics Inc. visualizedRisk-Managed Swing Setup and Signal Analysis - Newser
Using data models to predict Aptevo Therapeutics Inc. stock movementSafe Entry Screening with Data Backed Analysis - Newser
Aptevo Therapeutics Inc expected to post a loss of $83.20 a shareEarnings Preview - TradingView
Aptevo Therapeutics and 60 Degrees Pharmaceuticals to be Featured on Bloomberg TV's RedChip Small Stocks, Big Money Show - AInvest
Aptevo Therapeutics and 60 Degrees Pharmaceuticals Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - The Daily Corinthian
Aptevo Therapeutics (APVO) Expected to Announce Quarterly Earnings on Thursday - Defense World
Multi factor analysis applied to Aptevo Therapeutics Inc.Real Chart Based Opportunity Identification - Newser
How volatile is Aptevo Therapeutics Inc. stock compared to the marketDiscover top stock picks for aggressive growth - Jammu Links News
What institutional investors are buying Aptevo Therapeutics Inc. stockMaximize portfolio value with timely trades - Jammu Links News
Is Aptevo Therapeutics Inc. a good long term investmentMaximize portfolio growth with expert advice - Jammu Links News
How does Aptevo Therapeutics Inc. generate profit in a changing economyDiscover undervalued stocks ready to soar - Jammu Links News
How does Aptevo Therapeutics Inc. compare to its industry peersDiscover high-impact stocks for your portfolio - Jammu Links News
Is it the right time to buy Aptevo Therapeutics Inc. stockHigh-octane financial growth - Jammu Links News
How strong is Aptevo Therapeutics Inc. company’s balance sheetBuild a portfolio for long-term financial success - Jammu Links News
Why is Aptevo Therapeutics Inc. stock attracting strong analyst attentionCapitalize on emerging growth stocks - Jammu Links News
Does Aptevo Therapeutics Inc. stock perform well during market downturnsTremendous wealth creation - Jammu Links News
When is Aptevo Therapeutics Inc. stock expected to show significant growthInvest smarter with actionable market insights - Jammu Links News
What drives Aptevo Therapeutics Inc. stock priceUnlock daily market insights for better trades - Jammu Links News
What are the latest earnings results for Aptevo Therapeutics Inc.Build a portfolio for long-term financial success - Jammu Links News
Should I hold or sell Aptevo Therapeutics Inc. stock in 2025Unlock your trading potential today - Jammu Links News
What are Aptevo Therapeutics Inc. company’s key revenue driversBuild wealth faster with consistent growth stocks - Jammu Links News
What are the technical indicators suggesting about Aptevo Therapeutics Inc.Wealth Building Trend Scanner For Smart Trading - Jammu Links News
Aptevo Therapeutics Inc. Shows Support at Fibonacci LevelFree Elite Traders Group - beatles.ru
What is Aptevo Therapeutics Inc. company’s growth strategyInvest smarter with advanced market data - Jammu Links News
Aptevo Therapeutics Inc (APVO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.94%
1.72%
자본화:
|
볼륨(24시간):